IPO - Trevi Therapeutics, Inc.

Form Type: 8-K

Filing Date: 2025-06-04

Corporate Action: Ipo

Type: New

Accession Number: 000119312525134913

Filing Summary: On June 3, 2025, Trevi Therapeutics, Inc. entered into an underwriting agreement for an underwritten offering of 17,400,000 shares of its common stock at a public price of $5.75 per share. The underwriters, including Morgan Stanley & Co. LLC and others, agreed to purchase the shares at $5.405 each. An additional 2,610,000 shares can be purchased at the same price under a 30-day option. The net proceeds from the offering are estimated to be about $93.7 million, or $107.8 million if the additional shares are purchased. The closing of the offering is expected around June 5, 2025. The funds from the offering will be utilized for the clinical development of Haduvio for chronic cough treatment, operating expenses, and general corporate purposes. The Company believes current capital will suffice until 2029, but additional funding will be needed for future product candidates. The report includes forward-looking statements regarding the offering's completion and financial projections, alongside potential risks associated with market conditions and operational funding requirements.